Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Texas

Cancer biologic therapy trials in Texas

140 cancer biologic therapy studies are recruiting participants at sites in 53 cities across Texas as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Texas by city

Cities with the most studies recruiting right now.

Every Texas city with a recruiting study

By research area: Lymphoma (49), Lung Cancer (38), Breast Cancer (30), Melanoma (12), Prostate Cancer (6), Pancreatic Cancer (5).

Houston (101), Dallas (46), San Antonio (35), Fort Worth (18), Austin (16), Tyler (11), Sugar Land (10), El Paso (8), Lubbock (8), The Woodlands (7), Amarillo (6), Temple (6), Abilene (5), Baytown (5), Corpus Christi (5), Richardson (5), Conroe (4), League City (4), McAllen (4), Webster (4), Cypress (3), Flower Mound (3), Irving (3), Nassau Bay (3), Harlingen (2), Palestine (2), Weslaco (2), Wichita Falls (2), Allen (1), Arlington (1), Austin, TX 78758 (1), Beaumont (1), Bedford (1), Denison (1), Denton (1), Edinburg (1), Fredericksburg (1), Galveston (1), Garland (1), Grapevine (1), Humble (1), Laredo (1), Lewisville (1), Longview (1), McKinney (1), Midland (1), New Braunfels (1), Odessa (1), Paris (1), Pearland (1), Plano (1), Round Rock (1), Waco (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Texas

Basic details from each study's public record (the 12 most recently updated of 140). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Galveston
    Registry record
    NCT03606967 · updated
  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Abilene · Dallas · Houston · and 1 more U.S. location
    Registry record
    NCT05564377 · updated
  3. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Abilene · Amarillo · Dallas · and 6 more U.S. locations
    Registry record
    NCT06393374 · updated
  4. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Dallas · El Paso · Houston · and 1 more U.S. location
    Registry record
    NCT06841354 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Texas on ClinicalTrials.gov.

Lung cancer: recently updated in Texas

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Recruiting in
    Abilene · Austin · Dallas · and 4 more U.S. locations
    Registry record
    NCT06767514 · updated
  2. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Houston
    Registry record
    NCT06422143 · updated
  3. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Dallas · Houston · Tyler
    Registry record
    NCT06623422 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Texas on ClinicalTrials.gov.

Prostate cancer: recently updated in Texas

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Dallas · Fort Worth · Richardson
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Texas on ClinicalTrials.gov.

Lymphoma: recently updated in Texas

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Austin · Corpus Christi · Dallas · and 5 more U.S. locations
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Houston · San Antonio
    Registry record
    NCT06337318 · updated
  3. A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Sugar Land
    Registry record
    NCT05947851 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Texas on ClinicalTrials.gov.

Pancreatic cancer: recently updated in Texas

  1. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Houston
    Registry record
    NCT05372614 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Texas on ClinicalTrials.gov.

Ask about studies in Texas

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call